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Abstract
Background: Systemic hypertension (SH) is a potential complication of acute kidney
injury (AKI) in dogs.
Objective: To describe the prevalence of SH and hypertensive retinopathy in dogs
with AKI, to investigate the relationship between SH and severity of AKI and to
assess possible factors associated with SH.
Animals: Fifty-two dogs with AKI.
Methods: Prospective observational study of dogs presenting to a tertiary referral
center that fulfilled the International Renal Interest Society (IRIS) guidelines for the
diagnosis of AKI. Systolic blood pressure measurement, urine protein/creatinine ratio
(UPCR), urine output, presence of hypertensive retinopathy and fluid overload (FO),
survival to discharge and duration of hospitalization were subsequently assessed.
The prevalence of SH was calculated and the relationship between SH and recorded
factors was examined by nonparametric statistics.
Results: The prevalence of SH (≥160 mm Hg) on admission or during hospitalization was
75% (39/52) and in 56% (22/39) of cases this was severe (≥180 mm Hg). Sixteen percent
(7/43) of dogs had evidence of hypertensive retinopathy and 77% (24/31) dogs had
UPCR >0.5. Forty-two percent (22/52) dogs had FO on admission or during hospitaliza-
tion. There was no association between SH and IRIS AKI grade, oligo/anuria, survival to
discharge, duration of hospitalization or proteinuria. Dogs with FO on presentation were
more likely to be hypertensive at admission compared to dogs without FO (P = .02). Dogs
that did not survive to discharge were more likely to have FO (P = .007).
Conclusions and Clinical Importance: Systemic hypertension is common in dogs with
AKI. Systemic hypertension might be associated with FO, which itself is associated
with nonsurvival. Monitoring for SH and FO is therefore warranted in dogs with AKI.
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1 | INTRODUCTION
Acute kidney injury (AKI) is defined as an acute and abrupt decrease
in kidney function resulting in abnormal glomerular filtration rate
(GFR), tubular function and urine production.1 Systemic hypertension
(SH) is a potential complication of renal injury with variable occur-
rence in both dogs and cats with chronic kidney disease (CKD) and
AKI.2-5
Systemic hypertension (SH) can lead to target organ damage
(TOD), which includes hypertensive retinopathy, hypertensive
encephalopathy, left ventricular hypertrophy, and progression of kid-
ney disease. Hypertensive retinopathy occurs in both cats and dogs
with CKD and hypertensive retinopathy and left ventricular hypertro-
phy occurs in dogs with glomerular disease secondary to leishmania-
sis.3,6,7 The cause or causes of SH in kidney disease have yet to be
fully elucidated but theories include impaired excretion of sodium and
subsequent volume overload, excessive activation of the renin-angio-
tensin-aldosterone system, stimulation of the sympathetic nervous
system via activation of chemosensitive afferent fibers and increase in
systemic vascular resistance secondary to endothelial dysfunction.8,9
In dogs with CKD, there is a positive correlation between systolic
blood pressure (SBP) and degree of proteinuria and both SH and pro-
teinuria are associated with disease progression and reduced survival
time.3,10 The prevalence of SH in CKD in various studies ranges
between 9% and 93%.11 Based on retrospective studies 81% to 87%
of dogs with AKI have SH.4 The literature on the effect of SH on the
outcome of animals with AKI is sparse. Glomerular filtration rate is sig-
nificantly reduced in hypertensive dogs compared to nonhypertensive
dogs.12 However, in AKI in cats presence of SH has no effect on
survival.5
The primary aims of this observational study were to describe the
prevalence of SH and hypertensive retinopathy in dogs with AKI. The
secondary aims were to investigate the relationship between SH and
severity of AKI and to assess possible factors associated with SH. The
hypotheses were that SH would be common in dogs with AKI, but
ocular TOD would be less frequently detected. We further hypothe-
sized that there would be no association between SH, severity of AKI
or survival to discharge.
2 | MATERIALS AND METHODS
The study was approved by the Royal Veterinary College Clinical
Research Ethical Review Board (URN 2016 1590). Dogs presenting to
a university referral teaching hospital diagnosed with community
acquired AKI were prospectively recruited between July 2016 and
November 2018. Dogs were eligible for inclusion if they fulfilled the
International Renal Interest Society (IRIS) guidelines for the diagnosis
of AKI; known access to nephrotoxins, serum creatinine increase
>0.3 mg/dL over a 48 hour period or serum creatinine >1.6 mg/dL
with 1 or more of the following criteria; evidence of renal tubular
injury on urine analysis (renal glucosuria with normoglycemia, protein-
uria with an inactive sediment, urinary casts, or both), imaging findings
suggestive of AKI or oliguria (urine output <1 mL/kg/hr) over
6 hours.13
When available clinical records of the dogs were reviewed and
dogs were excluded if there was any historical physical examination
findings or previous clinicopathological data suggestive of CKD,
including weight loss, polyuria, or both, and polydipsia greater than
4 weeks in duration, and previously documented azotemia with urine
specific gravity <1.030. All dogs had renal ultrasound performed and
dogs were excluded if diagnostic imaging findings were indicative of
CKD. These included; small irregular kidneys and the presence of renal
infarcts. Dogs were also excluded if they failed to have an initial SBP
or serum creatinine concentration measurement, had a coexisting dis-
ease associated with SH (including hyperadrenocorticism, diabetes
mellitus, pheochromocytoma), were on medication which could result
in SH (glucocorticoids, ciclosporin, toceranib), or if they had been
treated with antihypertensive drugs such as angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, beta blockers, cal-
cium channel blockers, or acepromazine in the 48 hours before
enrolment.
The grade of AKI was determined by the first serum creatinine
concentration recorded from serum biochemistry (iLab 600, Instru-
mentation Laboratory, Cheshire, UK) when available, or bedside
venous blood gas and metabolite sample (ABL90 FLEX, Radiometer
UK Ltd, West Sussex, UK). The underlying cause of AKI was deter-
mined based on clinician interpretation of history and clinicopatholog-
ical data including hematology (ADVIA 212Oi, Siemens Healthcare,
Surrey, UK), serum biochemistry, microagglutination tests (Leptospiro-
sis MAT, IDEXX Laboratories, Horsham, UK), infectious disease test-
ing (SNAP 4Dx, IDEXX Laboratories, Horsham, UK), diagnostic
imaging, urinalysis, urine protein/creatinine (UPCR), urine culture, and
macroscopic and microscopic histopathological renal findings as
appropriate.
Systolic blood pressure was measured within 12 hours of admission
and at least once daily with Doppler sphygmomanometry. A standardized
protocol adapted from the American College of Veterinary Internal Medi-
cine (ACVIM) consensus guidelines was used; the dog was allowed to
acclimatize for 5 to 10 minutes before placement of a cuff (with cuff
width being 30%-40% of the circumference of the limb at the cuff site)
on either the forelimb or hindlimb, at the discretion of the operator. The
first measurement was discarded and a total of 5 to 7 consistent values
were taken, discarding any SBP reading >20% than the other SBP mea-
surements. The average of these readings was recorded.11
Based on criteria in the ACVIM guidelines dogs were grouped
based on their SBP and risk of TOD; normotensive
(SBP < 140 mm Hg), prehypertensive (SBP 140-159 mm Hg), hyper-
tensive (SBP 160-179 mm Hg) and severely hypertensive (SBP
≥180 mm Hg.11 Systemic hypertension was defined as a
SBP≥160 mm Hg. Where individual dogs had more than 1 series of
blood pressure readings performed on a given day, a median daily SBP
was used for analysis. Antihypertensive therapy was at the discretion
of the attending clinician.
Fundic examination was performed once within 48 hours of
admission by an American or European specialist in Ophthalmology or
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a supervised resident in training to assess for presence of hyperten-
sive retinopathy.11 Pupil dilatation was performed at the discretion of
the ophthalmologist on a case-by-case basis. The ophthalmologists
were unaware of the dog's SBP.
Urine output (UOP) was quantified either by measuring voided
urine, weighing bedding, or urethral catheterization. Oliguria was
defined as a urine output less than 1 mL/kg/hr for >6 hours.2 Fluid
overload (FO) was diagnosed by the attending clinicians who deter-
mined this based on a daily dog assessment including monitoring for
acute weight gain, serous nasal discharge, chemosis, subcutaneous
edema or detection of cavitatory fluid with ultrasonography.14 Pro-
teinuria was defined as UPCR >0.5 with an inactive sediment.15 Hypo-
albuminemia was defined as serum albumin concentration < 2.6 g/dL.
The IRIS grade of AKI, serum albumin concentration and UPCR
on admission were recorded. SBP, UOP and evidence of FO were
reviewed daily. Any change in AKI grade or SH classification during
hospitalization was recorded, alongside the use of antihypertensive
agents and any extracorporeal therapy. Hospitalization duration, sur-
vival to discharge, survival at 3 months and follow-up serum creati-
nine concentration and SBP where available were documented. The
prevalence of SH and hypertensive retinopathy were calculated.
2.1 | Statistical analysis
Data were assessed for normality by a Shapiro Wilks W test and a
visual inspection of histograms. Normally distributed data were
expressed as mean and standard deviation and non-normally distrib-
uted data expressed as median and ranges. Statistical analysis was
performed by statistical software (SPSS Statistics, Version 22.0, IBM).
Descriptive statistics were used to evaluate population character-
istics. A Fisher's exact test was used to compare categorical data
including number of dogs in each SBP category, AKI grade, presence
of FO, proteinuria and hypoalbuminemia, and survival. A Bonferroni
correction was used when comparing multiple categories. A Spe-
arman's rank correlation coefficient was used assess for correlation
between SBP, serum creatinine concentration and hospitalization
duration. The level of statistical significance was set at P < .05 and
adjusted as needed when using the Bonferroni correction.
3 | RESULTS
Fifty-six dogs presented with AKI between July 2016 and November
2018, of which 4 were excluded; 1 with prior history of antihyperten-
sive therapy and 3 with incomplete data. Fifty-two dogs were eligible
for inclusion in the study. Of these dogs 49 were pure breeds; the
most common pure breed was the Labrador (11/49) and 5/49 were
sighthounds. Three out of 52 dogs were cross-breeds. Nineteen (37%)
were male neutered, 18/52 (35%) female neutered, 7/52 (14%) female
entire and 8/52 (15%) male entire. The median age and mean weight
of dogs were 57 months (range 3-120) and 24.17 kg ±12.51, respec-
tively. Dogs presented with a variety of causes of AKI (Table 1).
Where a diagnosis was made, the most common were leptospirosis
(12%, n = 6), prior nonsteroidal anti-inflammatory drug use (12%,
n = 6) and hypercalcemia (12%, n = 6).
The median SBP on admission was 160 mm Hg (range 50-
275 mm Hg). The prevalence of SH (≥160 mm Hg) on admission was
54% (28/52) and in 43% cases (12/28) this was severe (≥180 mm Hg).
The median peak SBP at any time point was 175 mm Hg (range 90-
300 mm Hg). The prevalence of SH at some point during hospitaliza-
tion was 75% (39/52) which was severe in 56% cases (22/39)
(Table 2). Forty-three out of 52 dogs had a fundic examination during
hospitalization and 21% (9/43) of these had evidence of ocular TOD.
Two out of these 9 dogs, 1 in the normotensive category and the
other in the prehypertensive, did not have a hypertensive reading at
any point during their hospitalization. Fundic examination findings
included retinal hemorrhage (9/9), retinal vessel tortuosity (2/9), exu-
dative retinal detachment -complete (1/9)/multifocal (1/9) and
hyphema (3/9) (Figure 1A,B). Thirty-three percent (4/12) dogs that
underwent a postmortem examination had evidence of left ventricular
hypertrophy, 3 of 4 were hypertensive during hospitalization and 1
had retinal lesions.
Twenty-five out of 39 (64%) dogs diagnosed with SH at some
point during hospitalization were treated with antihypertensive drugs.
Those hypertensive dogs that did not receive antihypertensive ther-
apy had a short-lived hypertension (<48 hours) or died shortly after
hypertension was diagnosed. Of the treated dogs 22/25 (88%)
received amlodipine alone, 1/25 (4%) received benazepril alone and
2/25 (8%) received multiple antihypertensive drugs. One dog received
TABLE 1 Causes of acute kidney injury in 52 dogs presenting to
a tertiary referral center
Cause of AKI Number of dogs
Leptospirosis 6
NSAID use
– NSAID and GA















Ethylene glycol toxicity 2




GA and rhabdomyolysis 1
Rhabdomyolysis 1
Diagnosis not made 14
Abbreviations: AKI, acute kidney injury; CRGV, cutaneous and renal glo-
merular vasculopathy; GA, general anesthesia; NSAID, nonsteroidal.
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amlodipine, hydralazine and nitroprusside and the other received
amlodipine, hydralazine and telmisartan. Both of these dogs had
severe refractory hypertension (>200 mm Hg) and evidence of ocular
TOD. The dogs given telmisartan and benazepril were categorized as
AKI grade I and early grade III respectively. Choice of hypertensive
therapy was based on the clinician's discretion. The median daily dose
of amlodipine was 0.19 mg/kg (range 0.05-0.45 mg/kg). This was
given once a day in all dogs initially but was escalated to twice daily in
1 dog and given initially 3 times daily as incremental dose manage-
ment in another in attempt to manage severe hypertension. Antihy-
pertensive therapy was associated with a reduction in hypertension
category in 14/25 (56%) of cases; 2/14 severe to normotensive, 7/14
severe to prehypertensive, 3/14 severe to hypertensive and 2/14
hypertensive to normotensive. Twelve of the 25 (48%) dogs given
antihypertensive did not survive to discharge. Of the 13/25 (52%)
dogs given antihypertensive therapy that did survive to discharge 7/
13 (54%) were discharged on therapy, 4/13 (31%) had short lived
hypertension in hospital and 2/13 (15%) were discharged to be
euthanized.
The median serum creatinine concentration on presentation was
5.53 mg/dL (range 1.39-19.56 mg/dL). Five dogs out of the 52 (10%)
had grade I AKI, 2/52 (4%) grade II, 17/52 (33%) grade III, 17/52
(33%) grade IV and 11/52 (21%) grade V. Fourteen dogs (28%) had an
increase in AKI grade during hospitalization. There was no correlation
between initial SBP and serum creatinine on presentation (rs = 0.182,
P = 0.20). The prevalence of SH ranged between 50% and 91% across
AKI grades (Table 3). There was no association between the presence
of SH on admission or during hospitalization and IRIS AKI grade on
presentation or increase in AKI grade during hospitalization.
Twenty-nine out of 49 dogs were hypoalbuminemic (59%). The
mean serum albumin concentration was 2.53 g/dL ±0.54 (n = 49).
Thirty-four dogs had an UPCR measurement, of which 1/34 had gross
TABLE 2 Prevalence of systemic hypertension at admission and
during hospitalization in 52 dogs with acute kidney injury

























F IGURE 1 A, Focal retinal hemorrhage in a dog with acute kidney injury and systemic hypertension. B, Exudative retinal detachment in a dog
with acute kidney injury and systemic hypertension
TABLE 3 Prevalence of systemic hypertension and acute kidney
injury grade on admission in 52 dogs with acute kidney injury






Abbreviations: AKI, acute kidney injury; IRIS, International Renal Interest
Society.
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hematuria and 2/34 had an active sediment and so these dogs were
not included in further analysis. The median UPCR in the 31 remaining
dogs was 1.68 (range 0.1-18). Twenty-four out of 31 dogs (77%) had
UPCR >0.5 of which 14/24 (58%) had a UPCR above 2. There was no
association between presence elevated UPCR and hypoalbuminemia,
or SH on admission or during hospitalization.
A urinary catheter was placed in 54% (28/52) dogs. When consid-
ering all methods of urine measurement the median urine output was
1.4 mL/kg/hr over the entire hospital period ranging from 0 to
25 mL/kg/hr. Forty-two percent of dogs (22/52) were reported to be
oliguric (urine output <1 mL/kg/hr for >6 hours), all of which received
furosemide. Seven out of 20 dogs received a single bolus dose
between 0.5 and 2 mg/kg, 2/20 dogs had a bolus between 0.5 and
1 mg/kg before a continuous infusion of 0.1 to 2 mg/kg/hr and 11/20
had a continuous infusion between 0.25 and 0.8 mg/kg/hr. In 2 dogs,
the bolus dose of furosemide was not recorded. There was no associ-
ation between the presence of SH and the presence of oliguria or
anuria (P = .22). Six dogs had extracorporeal therapy, 4/52 (78%) had
continuous renal replacement therapy (CRRT) and 2/52 (4%) had total
plasma exchange. All 4 dogs that underwent CRRT were hypertensive
on admission.
Twelve dogs (23%) were considered to have FO on admission and
10/52 (19%) developed FO during hospitalization. Forty-two dogs
(81%) received intravenous therapy before admission and 94% (49/
52) received fluids at some point during hospitalization. In those dogs
with FO on presentation, fluid therapy was administered after furose-
mide in 6/10 (60%), extracorporeal therapy in 2/10 (20%) and for
replacement of varying insensible and sensible losses in 2/10 (20%)
dogs. There was a significant association between FO on admission
and SH on presentation (P = .02) but there was no association
between SH and the development of FO in hospital.
Twenty-five (48%) dogs survived to discharge and 3 dogs (6%)
were discharged home for euthanasia. Of those dogs that did not sur-
vive to discharge 22/24 (92%) were euthanized and 2/24 (8%) died.
The mean duration of hospitalization for the surviving dogs was
8.48 days ±4.13. There was no correlation between the SBP and hos-
pitalization duration for dogs that survived (rs = 0.225, P = .28). There
was no association between survival to discharge and SH on admis-
sion or during hospitalization, nor was there an association between
IRIS AKI grade and survival. There was an association between the
presence of FO at any point during hospitalization and survival to dis-
charge (P = .007).
In those dogs that survived to discharge, 32.0% (8/25) were lost
to follow-up. Out of the remaining dogs 29% (5/17) died within
3 months. Of the 5 dogs that died within 3 months, 2/5 were eutha-
nized directly as a result of their AKI, 2/5 were euthanized as result of
an underlying neoplastic process and 1/5 died of unrelated causes.
Overall 3-month survival rate of all dogs available for follow-up was
28% (12/44). The presence of SH at admission and during hospitaliza-
tion was not associated with 3-month survival. Five out of 10 (50%)
dogs that had serum creatinine measured within the 3 month follow-
up period after discharge had a serum creatinine above the upper limit
of the laboratory defined value of >1.63 mg/dL. All of these dogs
were hypertensive at some point during hospitalization. Four out of 5
dogs that had blood pressure measurements between 2 and 12 week
after discharge were found to be hypertensive and on therapy.
4 | DISCUSSION
This prospective study shows that the prevalence of SH is high in
dogs with community acquired AKI and appears to increase during
hospitalization; 54% of dogs were hypertensive on presentation and
43% had severe hypertension. These values increased to 75% and
56% respectively during hospitalization. These results are similar to
the currently reported SH occurrence rate of 81% to 87% in dogs with
AKI during hospitaliszation.4 There is therefore a clear requirement
for frequent blood pressure monitoring of animals hospitalized
with AKI.
Hypertensive retinopathy was detected in 16% dogs in this study.
This is less than reported in a study of all causes of hypertension,
which report a prevalence of 62%.16 However, the prevalence is simi-
lar to that previously described in dogs with CKD.3 The low preva-
lence of hypertensive retinopathy could be explained by the low
number of dogs presenting with severe hypertension, the low rate of
repeat ophthalmological examinations, or failure to detect early retinal
lesions, as pupil dilatation was not performed in all dogs. Two dogs, 1
in the normotensive category and 1 in the prehypertensive category,
also had retinopathy consistent with hypertension. One of the dogs
had AKI secondary to a combination of presumed renal hypotension
secondary to general anesthesia and laparoscopy, and nonsteroidal
anti-inflammatory drug therapy. Retinal hemorrhage occurs in humans
undergoing laparoscopic surgery suspected to be secondary to
increased retinal venous pressure17 and therefore could explain this
finding. Alternatively, these findings could be explained by underesti-
mation of the diagnosis of hypertension as a result of inherent inaccu-
racies of indirect measures of SBP, or could suggest that macroscopic
retinal vascular changes are not sensitive indicators of early ocular
TOD. Studies of early stage untreated essential hypertension in
humans failed to find a relationship between retinal microvascular
changes and other validated markers of TOD such as 24-hour ambula-
tory blood pressure monitoring, 24-hour urine collection for
microalbuminuria, echocardiography, and carotid ultrasonography.18
Despite the seemingly low prevalence of hypertensive retinopathy in
AKI, systemic heparinization in the presence of retinal hemorrhage
could lead to severe retinal damage. An ophthalmological exam should
therefore be considered in all AKI dogs before CRRT.
There was no association between evidence of hypertensive reti-
nopathy and severity of SH. This might be the result of a type II error
because of the low numbers of dogs with evidence of hypertensive
retinopathy or the temporal relationship between detection of SH and
fundic examination. Fundic examination was standardized to occur in
the first 48 hours and the number of severely hypertensive dogs at
admission was low. Another factor shown to affect the development
of TOD in people is the variability of SBP; greater variability of SBP
has been shown to associated with greater risk of TOD.19 SBP
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variability was not assessed in this study but is something that should
be considered in future studies.
Left ventricular hypertrophy, indicative of cardiac TOD has been
reported in 91% of hypertensive dogs with leishmaniasis, of which
over half of the dogs had kidney disease.7 In our study, 4/12 dogs that
underwent a postmortem examination had evidence of left ventricular
hypertrophy, of which 3 quarters of them were noted to be hyperten-
sive during hospitalization and 1/4 had retinal changes. These findings
suggest a degree of chronicity of the SH and therefore might indicate
a failure to diagnose CKD in this subset of dogs. However, the possi-
bility of the AKI occurring secondary to SH cannot be excluded. These
results suggest other diagnostic tests such as echocardiography
should be used alongside a fundic examination to further assess
for TOD.
Proteinuria has been associated with SH and persistent protein-
uria is considered a finding indicative of TOD.11,20 Studies report a
positive but nonlinear correlation between SBP and UPCR in
dogs.10,12,21 Proteinuria might also be the result of primary glomerular
disease. A UPCR >2 alongside hypoalbuminemia is considered consis-
tent with glomerulonephropathy15 and SH has been shown to associ-
ated with glomerular disease in dogs.7 In our study, over 75% dogs
had a UPCR >0.5 of which 58% had UPCR >2. Few previous studies
have quantitatively assessed proteinuria in AKI dogs; 78% dogs with
leptospirosis were reported to have an elevated UPCR22 and in
another study of 125 dogs UPCR values between 0.09 and 72 were
reported in dogs with AKI of all causes and the degree of proteinuria
was significantly greater in nonsurvivors.23 In the current study there
was no association between proteinuria and hypoalbuminemia, SH
and survival to discharge. Failure to detect an association between SH
and proteinuria might be the result of a type II error because of the
small number of dogs with UPCR measurement or secondary to the
effect of treatment; hypertensive dogs were treated at the clinician's
discretion and many had improvement in their SBP category which
could have masked an association between SH and proteinuria. Alter-
natively, the proteinuria could have been predominantly tubular in ori-
gin rather than a result of glomerular hypertension. Future studies
with renal biomarkers of glomerular and tubular injury such as frac-
tional excretion of IgG and IgM and urine neutrophil gelatinase-associ-
ated lipocalin (NGAL) alongside trending of UPCR in dogs with AKI
over time might help determine the origin of this proteinuria and
could have consequences of the choice of antihypertensive therapy.
There was no association between the presence of SH and IRIS
AKI grade or absolute serum creatinine concentration. This is similar
to findings in cats with AKI and in dogs with cardiorenal syndrome.5,24
These finding suggests SH can occur at all grades of AKI. Interestingly,
canine studies have shown a reduction in GFR correlates with an
increase in SBP.10,12 In an experimental canine study, hypertensive
dogs had a significantly reduced GFR and increase in renal tubular
lesions and fibrosis compared to normotensive dogs in the weeks to
months after AKI, suggesting SH has appreciable adverse effect on
kidney structure and function12 In the current study SH was treated
at the clinician's discretion and hypertensive category reduced in
around half of the dogs. This intervention could have masked the
potential effect of SH on disease progression and outcome. Further-
more, the number of cases loss to follow-up was high and up sampling
was not standardized reducing the study's power to detect the long-
term effect of SH on kidney function. Finally, the IRIS guidelines used
in this study for grading AKI are based on serum creatinine concentra-
tions alone which is not considered an accurate indicator of GFR.13,25
Future studies should therefore consider the routine use of commer-
cial measures of GFR at standardized follow-up time points.
There was no association between SH at admission or develop-
ment during hospitalization and survival nor between AKI grade and
survival to discharge. The failure to detect an association between SH
and survival to discharge is similar to that reported in cats with AKI.5
Dogs enrolled had no pretreatment with antihypertensive agents and
therefore we can reliably assess the effect of previously untreated SH
on admission with disease severity and outcome. However, during
hospitalization antihypertensive therapy was administered at the clini-
cian's discretion and in around half of treated dogs their hypertension
resolved. It is therefore difficult to elucidate the effect of persistent
hypertension on outcome in this study. It is plausible that antihyper-
tensive therapy masked the effect of SH on survival. The lack of asso-
ciation between severity of AKI and outcome is surprising and
contrary to previous studies of AKI whereby increased AKI grade was
associated with worsened outcome.23,26,27 This difference could be
explained by differences in causes of AKI in our population versus
others and the over-reaching effect of etiology on outcome in AKI
irrespective of absolute serum creatinine concentration. The study's
small size, particularly the number of dogs in lower AKI grades, might
also contribute to failure to detect an effect of AKI grade and
outcome.
Of those dogs which survived and for which information was
available, 50% were azotemic on 1 or more occasion after discharge.
All of these dogs were hypertensive at some point during hospitaliza-
tion. Inferences on the effect of SH on development of CKD cannot
be made given the small number of dogs, but this supports the need
for regular monitoring of dogs after an episode of AKI. Only 5 dogs
had follow-up blood pressure, of which 4/5 were persistently hyper-
tensive and on antihypertensive therapy. Monitoring blood pressure
after discharge is particularly important considering human AKI dogs
are more likely to develop hypertension during follow-up.28
Despite the frequent occurrence of SH in dogs with kidney dis-
ease the pathogenesis is poorly understood. Suggested etiologies
include volume impaired excretion of sodium leading to volume over-
load, excessive activation of the renin angiotensin-aldosterone sys-
tem, stimulation of the sympathetic nervous system secondary to
activation of chemosensitive afferent neurons by local ischemia and
inflammation, reduced bioavailability of the vasodilator nitric oxide
and increased production of the vasoconstrictor endothelin. 8,9 In this
study the presence of SH at admission was associated with the pres-
ence of FO at admission suggesting a role for volume and sodium
excess in the pathogenesis of hypertension in this population. It is
unclear why this relationship did not persist during hospitalization but
the authors hypothesize it is related to the duration of FO; during hos-
pitalization daily frequent monitoring of weight encourages early
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detection of FO. This might prompt the de-escalation of fluid therapy
before the development of clinically detectable volume overload. In
human dialysis, dogs' volume status, particularly those with FO are
associated with both predialysis and postdialysis blood pressure.
Blood pressure falls during hemodialysis with fluid removal and the
decrease in blood pressure is greatest with larger amounts of fluid
removal and with higher ultrafiltration rates.29 In the current study, 4
dogs underwent CRRT as part of their management, all of which were
hypertensive. SH did not resolve after therapy in any of the dogs,
despite resolving their FO, suggesting this might only partly contribute
to SH in AKI. Further studies of volume status in dogs with AKI and
SH, using standardized measures of volume status such as bio-
impedance are required. In this study the presence of FO at any point
during hospitalization was also associated with a reduced survival to
discharge and this is consistent with studies in critical dogs and people
undergoing renal replacement therapy.30,31 This finding highlights the
need for careful monitoring and judicious fluid therapy dogs with AKI.
Amlodipine at a daily dose range of 0.1 to 1.2 mg/kg was the pre-
dominant therapy for hypertension used in this study. One dog received
a dose above the recommended range of 0.1 to 0.5 mg/kg PO11 similar
to a previous study where doses up to 1 mg/kg were required.4 Despite
treatment, the hypertensive category only reduced in around half of the
treated dogs. Failure to achieve control is likely because of failing to
appropriately adjust antihypertensive medication in light of persistent
hypertension, particularly in those dogs that had shorter survival times.
Additional contributing factors include; the potential for reduced oral bio-
availability of amlodipine in critically ill dogs32 and secondary glomerular
hypertension as a consequence of preferential afferent arteriole vasodila-
tation with amlodipine therapy.11 Further studies assessing amlodipine
levels, proteinuria, and continuous blood pressure measurements in criti-
cal AKI dogs are required to best determine the dose and role of the drug
in these dogs.
This study had several limitations. It was conducted in a referral
center and therefore the availability of complete medical records
before referral was variable and the majority of dogs received treat-
ment, including fluid therapy, before referral. The diagnosis of FO
involved subjective assessment and was therefore less accurate than
determining fluid balance based on calculations of fluid in and fluids
out and the use of bioimpedance techniques.
AKI grade was determined based on the first recorded serum cre-
atinine concentration and therefore the method of measurement was
not standardized. This could lead to inter-individual variation in serum
creatinine concentration and could affect subsequent AKI grading.
Furthermore, only 7 dogs with IRIS AKI grade I and II were enrolled
reducing the distribution of data. Being a clinical study there was no
predefined guidelines for management of SH, nor was there a control
untreated group of dogs. This, therefore, limits the study's power to
determine the effect of SH on AKI severity and outcome. Further-
more, there was no standardization of management of dogs once dis-
charged and there was a high occurrence of loss to follow-up of dogs
that survived to discharge. This, thereby, limits the assessment of the
effect of SH on long-term kidney function. Further studies should
focus on the efficacy of predefined antihypertensive therapy and
routine follow-up including serum creatinine and other biomarkers of
kidney function, urinalysis and GFR measurements to fully assess the
effect of SH and development of CKD.
Situational hypertension, an increase in blood pressure as a result
of adrenergic stimulation during situations of stress or anxiety, is diffi-
cult to control in any clinical study.11 Situational hypertension has
been documented in hospitalized dogs, in particular grey-
hounds.31,33,34 Furthermore, greyhounds have significantly higher
SBP than other breeds.35 In this study, there were 5 sighthounds and
3/5 were considered hypertensive, of which 2 had SBP over
180 mm Hg. Although in the majority of studies the increase in blood
pressure in the hospital was marginal, values up to 200 mm Hg are
reported and therefore the presence of situational hypertension could
lead to misclassification of dogs in all hypertensive categories.35,36
Despite hospital protocols being in place to minimize the effect of
stress on the blood pressure readings and following ACVIM guide-
lines11 to measure blood pressure, the prevalence of SH in this study
might have been increased by dogs with solely situational hyperten-
sion. Continuous blood pressure monitoring would be required to fully
mediate the effect of situational hypertension.
Doppler sphygmomanometery is a recognized indirect measure of
blood pressure. However, indirect blood pressure measurements have
been shown to underestimate SBP in the hypertensive dog and there-
fore using this methodology might have underestimated the true
prevalence of SH.37 The gold standard technique for measurement of
blood pressure is direct arterial catheterization, but is not practical in
this subset of dogs. Telemetric blood pressure measurement could be
useful both during hospitalization and after discharge to reliably
detect SH, TOD and the effect of treatment in dogs with AKI.38
In summary, SH is common in dogs with AKI. However, hyperten-
sive retinopathy appears to be uncommon. Systemic hypertension can
occur at all grades of AKI and therefore SBP should be monitored in
all dogs with AKI irrespective of severity. Systemic hypertension on
admission does not appear to affect outcome, however, in light of the
routine use of antihypertensives the effect of persistent SH on out-
come cannot be fully elucidated from this study. The relationship
between FO and SH needs to be further explored but considering FO
was associated with worsened outcome measures should be taken to
monitor for, and prevent FO in dogs with AKI.
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